Alzheimer's Disease and Dementia
Featured Topics
Lead story
Other featured articles
-
Vast Majority of Dementia Patients Don’t Receive Specialty Diagnosis and Care, Study Finds
Researchers found the use of dementia specialty care is particularly low for Hispanics and Asians.
Posted in -
Alzheimer’s-Preventing Drugs May Already Exist – We Just Can’t Test Them
Many people who use statins to fight heart disease seem to be on a slower track for developing Alzheimer’s compared to the rest of the population. Yet multiple hurdles stand in the way for this sort of study.
Posted in -
Some Blood Pressure Medications May Reduce Risk of Alzheimer’s, But Not For All Populations
Certain antihypertensive medications may prevent the onset of the disease, but only among black and white women and white men.
Posted in -
The Value of Delaying Alzheimer’s Disease Onset
Models show that the number of patients will more than double in 40 years, and costs associated with their care will nearly quintuple.
Posted in
About this section
Even small delays in the onset of Alzheimer's disease and dementia could have significant impacts for the patient, their family and caregivers, and the healthcare system more broadly. The Schaeffer Center's microsimulation models demonstrate there may be preventive measures we can take now to shape the nation's future health.
OUR EXPERTS ON ALZHEIMER'S DISEASE AND DEMENTIA PREVENTION
Our Work In Alzheimer's Disease and Dementia
-
The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey
Research by Jakub Hlavka and colleagues suggests a combination of brief cognitive tests and blood-based biomarker tests will allow primary care physicians to identify patients with potential early stage Alzheimer’s disease efficiently and triage them for further evaluation.
Categorized in -
Supported by $2.33 Million National Institute on Aging Grant, Researchers Aim to Ensure Access to Future Alzheimer’s Treatments
Dana Goldman and Darius Lakdawalla are evaluating affordable ways to address the rising number of Alzheimer’s disease and related dementias patients, including developing novel reimbursement frameworks, to ensure these patients have access when an innovative treatment becomes available.
-
Are We Ready to Treat Alzheimer’s?
Alzheimer’s research has been associated with many more downs than ups, but with Biogen’s surprising decision to file for market authorization of aducanumab, the next major challenge is for national healthcare systems to get ready.
Categorized in -
Measuring Alzheimer’s Disease and Other Dementias in Diverse Populations Using Medicare Claims Data
The researchers examined how methods used for identifying dementia in administrative claims affected dementia incidence across racial/ethnic populations using a 100% sample of Medicare beneficiaries.
-
Longitudinal Analysis of Dementia Diagnosis and Specialty Care Among Racially Diverse Medicare Beneficiaries
The burden of Alzheimer’s disease and other dementias is rapidly growing. Researchers found vast majority of dementia patients don’t receive specialty diagnosis and care.
-
Assessing the Preparedness of the Canadian Health Care System Infrastructure for an Alzheimer’s Treatment
A report on Canadian readiness to deal with new Alzheimer’s disease treatments co-authored by Jakub Hlávka found that average wait times could reach 28 months and that the most pressing issue is a lack of dementia specialists.
Categorized in